Category: Greatbatch Inc.
Greatbatch files for European CE Mark for its spinal cord stimulation system, hoping to land marketing approval the treatment of chronic pain of the trunk and limbs.
Greatbatch (NYSE:GB) filed a CE Mark application for its spinal cord stimulation system with German notified body TÜV SÜD America.
Greatbatch files a pre-market approval application for its spinal cord neuromodulation system for treatment of chronic pain of the trunk and limbs.
Greatbatch (NYSE:GB) this week filed a pre-market approval application with the FDA for its spinal cord neuromodulation system.
The neuromodulation system comes from the Frisco, Texas-based company's subsidiary, QiG Group, which hopes to win indication to treat chronic pain of the trunk and limbs.
Greatbatch swings to 3rd-quarter profits and beats Wall Street's earnings expectations, sending share prices up today.
Greatbatch (NYSE:GB) shares are up this morning after the medical device company reported a profitable 3rd quarter and beat Wall Street's expectations for per-share earnings.
Uroplasty fills its chief finance officer spot with the former CFO of Synovis, a company acquired by Baxter.
Uroplasty (NSDQ:UPI) named Brett Reynolds to head its vacant finance chief position, drawing the new executive from his most recent gig as CFO at Baxter- (NYSE:BAX)acquired Synovis Life Technologies.
After releasing Q2 earnings, Texas medical device maker Greatbatch raises per-share guidance for the 2nd time in 2 months.
Texas medical device maker Greatbatch (NYSE:GB) posted a profit in Q2 and nudged its 2013 per-share earnings guidance up for the 2nd time in 2 months. The device maker's Q2's sales eked out a 3% boost over last year's figures and profits were up 10%, according to the financial release.
Greatbatch merges its sales, marketing and operations with subsidiary Electrochem in the interest of shifting from sub-assemblies to complete medical devices, raising its 2013 per-share earnings guidance.
Texas medical device maker Greatbatch (NYSE:GB) raised its 2013 per-share earnings guidance as it announced new efforts to reorganize some of its business practices and reduce costs as it shifts from a components and sub-assemblies company to a developer of full medical devices.
Edwards Lifesciences CEO Michael Mussallem updates investors on U.S. sales expectations for its flagship Sapien heart valve and says the end might be near for its long legal battle with Medtronic's CoreValve over transcatheter aortic valve implant patents covering Sapien.
Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.